HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxane

PURPOSE: To assess whether crofelemer would prevent chemotherapy-induced diarrhea (CID) diarrhea in patients with HER2-positive, any-stage breast cancer receiving trastuzumab (H), pertuzumab (P), and a taxane (T; docetaxel or paclitaxel), with/without carboplatin (C; always combined with docetaxel r...

Descripción completa

Detalles Bibliográficos
Autores principales: Pohlmann, Paula R., Graham, Deena, Wu, Tianmin, Ottaviano, Yvonne, Mohebtash, Mahsa, Kurian, Shweta, McNamara, Donna, Lynce, Filipa, Warren, Robert, Dilawari, Asma, Rao, Suman, Mainor, Candace, Swanson, Nicole, Tan, Ming, Isaacs, Claudine, Swain, Sandra M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9633499/
https://www.ncbi.nlm.nih.gov/pubmed/36280642
http://dx.doi.org/10.1007/s10549-022-06743-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9633499/
https://www.ncbi.nlm.nih.gov/pubmed/36280642
http://dx.doi.org/10.1007/s10549-022-06743-9

Ejemplares similares